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Multiple System Atrophy (MSA) consists of three disorders;
Autonomic Dysfunction, Cerebellar Ataxia, and Parkinsonism. In MSA, the
protein Alpha-Synuclein (SNCA) appears in the central nervous system as
misfolded protein aggregates primarily in oligodendrocytes. This dissertation
reports the results from studies examining the effect of exogenous SNCA has
on a cell model: C6 oligodendrocyte-like cells. Treated cells were evaluated
using western blot and DNA microarray. In addition the expression of
proteins was evaluated using immunocytochemistry in MSA patient tissue.
C6 cells were shown to take up SNCA when added to the media. SNCA
also underwent a truncation when taken up by C6 cells. SNCA induced cell
death in C6 cells in a dose-dependent manner. SNCA also induced changes
in expression of Caspase 3 (CASP3), a marker for apoptosis.
In C6 cells treated with SNCA, two apoptosis-related genes,
Programmed Cell Death 4 (PDCD4) and Pancreatic Derived Factor (FAM3B)
showed changes in protein expression. These changes appeared to

correspond to expression of CASP3. In MSA patients, FAM3B, PDCD4 and
CASP3 appeared to be expressed in fibers containing myelin basic protein, a
marker for oligodendrocytes, suggesting a relationship with the disease.
Cells treated with SNCA undergo changes in gene expression. In cells
treated with SNCA, 3 genes were upregulated and 20 genes were
downregulated. Many of these genes were related to microtubules, apoptosis
and/or the AKT/PI3K/mTOR pathway.
One gene of interest, Hook Homolog 3 (HOOK3), was evaluated via
western blot. After treatment with SNCA, HOOK3 protein showed a decrease
in expression that confirmed the decrease in gene expression of HOOK3
observed in the DNA microarray. In MSA patients, HOOK3 co-localized with
SNCA in the granule cell layer of control patients and decreased in granule
cell layer of MSA patients. Interestingly, as HOOK3 and SNCA decreased in
the granule cell layer, HOOK3 co-localized with SNCA in the white matter
tracks of MSA patients.
Overall these results confirm that C6 cells treated with exogenous
SNCA function as a model for MSA. The treatment of SNCA also appeared to
influence proteins related to the AKT/PI3K/mTOR pathway, potentially
regulating apoptosis.
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CHAPTER I
AN INTRODUCTION TO MULTIPLE SYSTEM ATROPHY
Multiple System Atrophy (MSA) is a condition, similar to
Parkinson’s Disease (PD), but consists of three disorders; autonomic
dysfunction, cerebellar ataxia, and parkinsonism. MSA compromises
functions such as balance, blood pressure, breathing, swallowing, and
fine motor control. Aggregates of the protein α-Synuclein (SNCA,
NACP, non A4 component of amyloid precursor) appear in the central
nervous system (CNS) as cellular inclusions in MSA (Duda et al, 2000),
as well as in other diseases, (e.g., PD, and Alzheimer’s disease with
Lewy Bodies) referred to as synucleinopathies (Ueda et al. 1993,
Spillantini et al. 1995, Polymeropoulos et al. 1997, Langerveld et al.
2007). In MSA, synuclein aggregates appear primarily in
oligodendrocytes as glial cytoplasmic inclusions (GCI) (Tu et al. 1998).
Both myelinating oligodendrocytes and associated neurons appear to
die in MSA, but the role of SNCA in MSA is unknown.
Inclusion bodies in the brain of Alzheimer’s patients were first
identified by isolating an unknown protein and generating an
expression library. SNCA was identified as the non-Amyloid beta
fragment (non-amyloid component, NAC) of the Amyloid protein found
in Alzheimer’s. (Ueda et al. 1993) This fragment is thought to be the
cause of aggregation in Lewy bodies (Iwia, et al., 1995,).
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Due to the occurrence of Lewy body aggregation in both
Alzheimer’s and Parkinson ’s disease, the DNA sequence of the NAC
fragment (SNCA) was examined in PD patients. SNCA was found to be
located on the 4q21 chromosome of PD patients (Ueda et al. 1993,
Spillantini et al. 1995). Immuno-staining of SNCA showed
accumulation in the Lewy bodies of PD patients (Spillantini et al.
1997). Identification of SNCA allowed for the comparison of DNA in
families with PD, resulting in identification of three point and two
duplication mutations in the SNCA gene. The first mutant A53T was
shown to be an autosomal dominant point mutation occurring in
families with a history of PD (Polymeropoulos et al. 1997). Following
this discovery, two more point mutations, E46K and A30P were also
identified to be heritable mutations in PD (Vaughan et al. 1998,
Kruguer et al. 2001). In addition to point mutations, duplication of the
normal SNCA gene in families with PD was also shown as a cause for
Lewy bodies (Ibanez et al., 2004).
The SNCA protein contains 140 amino acids and has similar
functional and structural homology to 14-3-3 class proteins. SNCA will
also bind with 14-3-3 class proteins, BAD and Protein Kinase C
proteins (Ostrerova et al, 1999). SNCA acts as a chaperone with
synphilin 1 in the exocytosis of vesicles of the presynaptic region of
axons (Shirakashi et al. 2005), and in the recycling of vesicles involved
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in dopamine neurotransmitter release by binding to fatty acids and
regulating phospholipase D2 (Lotharius and Brundin 2002). SNCA also
binds with actin, reducing the rate of polymerization and increasing
depolymerization (Sousa et al. 2009). Under normal conditions, SNCA
is bound by lysosomal-associated membrane protein 2 (LAMP2a) and
heat shock conjugate 70 (HSC70) for degradation by the lysosome
(Cuervo 2010). The amino acid substitution that occurs in A53T
results in a reduction in the transport of SNCA into the lysosome
(Cuervo et al. 2004).
SNCA has been shown to induce cell death in a variety of
experiments. Cultures of rat neuronal hippocampal progenitor (H19-7)
cells show increases in cell death as treatment dose of SNCA increases
(Sung et al. 2001). In a co-culture, SH-SY5Y cells transfected with the
adeno/SNCA gene were shown to produce SNCA protein and supply rat
primary cortical neurons and mouse cortical neuronal stem cells with
SNCA through endocytosis. This transfer resulted in apoptosis via
induction of Caspase 3 in cortical neurons (Desplats et al. 2009).
Additionally in another study, cultured SH-SY5Y cells with
overexpressed A53T mutant, or wild type SNCA, showed localization of
A53T and SNCA WT with the mitochondrial membrane, releasing
Cytochrome C, leading to oxidative stress-induced apoptosis (Parihar
et al. 2008). Glial cells transfected with a gene overexpressing SNCA
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were shown to increase apoptosis due to oxidative stress (Stefanova
et, al 2001).
In other experiments the SNCA gene was transfected into
oligodendrocytes to produce neuropathology (Shults et al., 2005,
Tsuboi et al., 2005). Cultured oligodendrocytes transfected with SNCA
and another gene, p25α, that induces SNCA aggregation, resulted in
Caspase 3-induced apoptosis (Kragh et, al 2009).
In MSA, significant apoptosis has been shown to occur in
oligodendrocytes, but not neurons (Probst-Cousin et al., 1998). This is
different from PD where apoptosis primarily occurs in neurons.
Oligodendrocytes may lack the ability to deal with the quantity of
SNCA a neuron normally contains due to its role in transport of
synaptic vesicles to distant terminals. In MSA, neurons and/or other
cell types might make misfolded SNCA, which is then taken up by the
oligodendrocytes resulting in cell death. Oligodendrocytes might also
be modifying SNCA in an inappropriate manner resulting in
aggregation of the protein.
Thus, the objectives of the present study were first to determine
if oligodendrocyte-like cells can take up exogenous SNCA in vitro;
second, to determine if uptake induces apoptosis and related gene
expression. C6 cells are a rat glial cell line originally isolated from rat
gliomas that expressed S100 protein. Depending on growing
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conditions, these cells can be differentiated into astrocyte or
oligodendrocytes-like cells. When treated with retinoic acid, C6 cells
differentiate into oligodendrocyte-like cells that express myelin
proteolipid protein (Lopez-Barahona et al. 1993, Zhang et al. 2001).
Thus, C6 oligodendrocyte-like cells serve as a model system to study
the effects SNCA has on Oligodendrocytes.
An additional objective of this study was to confirm the presence
of proteins in MSA patients that were shown to change expression in
C6 oligodendrocytes due to treatment with SNCA. To accomplish this I
used paraffin embedded sections of cerebellum from patients that
have passed on due to MSA. These tissue sections were analyzed using
immunocytochemistry methods.
Chapter 2 examines if C6 cells uptake exogenous SNCA, how
uptake is influenced by SNCA concentration, and if SNCA induces
changes in a protein found in GCIs in MSA. Cells were treated with
wild-type SNCA or a familial mutant SNCA A53T, to determine if C6
cells would take up both types of exogenous SNCA. Next I evaluated
how the concentration of SNCA in media influenced the quantity of
SNCA taken up by the cells. To confirm that SNCA induced changes in
cell physiology, a protein (Heat shock conjugate 70, HSC70) known to
occur with SNCA in GCIs was measured via western blot analysis.
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Chapter 3 describes how SNCA induces cell death and apoptosis
in C6 oligodendrocytes. Cells were treated with increasing
concentrations over 2 and 4 days. After treatment, viability of the cells
was tested using a trypan blue assay. To measure apoptosis,
expression of Caspase 3 (CASP3), the effector protein in apoptosis,
was measured using western blot analysis.
Chapter 4 describes how DNA microarray analysis was used to
determine global gene expression patterns influenced by SNCA
treatment of C6 cells. This experiment created a “roadmap” of gene
expression changes related to SNCA uptake in C6 oligodendrocytes.
Thus, C6 cells were treated at two concentrations of SNCA for 4 days.
After treatment mRNA extracted from cells was hybridized to
Affymetrix DNA microarrays and scanned. The results from the two
SNCA treatments were compared to results from control cells.
Messenger RNA from one gene of interest, Hook Homolog 3 (HOOK3),
was regulated by SNCA treatment in the Affymetrix study. To confirm
SNCA-induced changes in expression, HOOK3 protein was measured
using western blot analysis.
Chapter 5 examines two genes of interest related to apoptosis.
Programed Cell Death 4 (PDCD4) and Pancreatic-derived Factor
(PANDER, FAM3B) were shown to occur in two separate DNA
microarray studies of MSA patients (Ide et al., unpublished data,
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Langerveld et al., 2007). Using western blot analysis I examined how
the concentration of SNCA affected expression of these two proteins in
C6 cells. To confirm the involvement of FAM3B in MSA, I used
Immunocytochemistry (ICC) methods to stain for the presence of
FAM3B with Myelin Basic Protein (MBP, a marker for oligodendrocytes)
in the white matter tracts of MSA patients.
Chapter 6 examines the expression of HOOK3 and SNCA in
control and MSA patient cerebellum. As discussed in chapter 3, HOOK3
was shown to be influenced by SNCA treatment of C6 cells. HOOK3, a
member of the Hook family, binds to microtubles and golgi (Walenta et
al., 2001). SNCA has been known to interact with Microtubule
Associated Protein Tau (Spillantini et al., 1999) and Beta Tubulin 3
(Nakayma et al., 2009). As such, using ICC methods, I stained the
granule cell layer and white matter tracts for HOOK3 and SNCA in MSA
and control patients. Samples were photographed and the area of
HOOK3 and SNCA contained in the granule cell layer was measured.
In conclusion, chapter 7 examines how C6 cells function as a
model for MSA. In addition I summarize how many of the genes
evaluated in this study have interactions with the pathways AKT and
PKC. Using this data I formulate a theory of how SNCA influences
apoptosis in Oligodendrocyte like cells. Understanding how apoptosis
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is influenced by SNCA oligodendrocytes could be useful in preventing
cell death of oligodendrocytes and associated neurons in MSA.
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CHAPTER II
ALPHA-SYNUCLEIN UPTAKE BY C6 OLIGODENDROCYTE-LIKE CELLS
INDUCES CHANGES IN EXPRESSION OF HEATSHOCK CONJUGATE 70,
A PROTEIN KNOWN TO ACCUMULATE IN MULTIPLE SYSTEM ATROPHY
Introduction
As stated in chapter 1, MSA is a member of diseases referred to
as synucleinopathies (Ueda et al. 1993, Spillantini et al. 1995,
Polymeropoulos et al. 1997, Langerveld et al. 2007). Both
oligodendrocytes and associated neurons die in MSA, but the role of
SNCA is unknown. In MSA, SNCA aggregates appear primarily in
oligodendrocytes as GCI (Tu et al, 1998). To date oligodendrocytes
have not been shown to produce SNCA, suggesting that
oligodendrocytes take up SNCA from an exogenous source.
Previous studies have shown that both neurons and glia have the
capacity to take up exogenous SNCA through endocytosis (Sung et, al.
2001, Ahn et al. 2006, Liu et al. 2007, Liu et al. 2009). In a co-culture
experiment, neurons took up misfolded SNCA provided by other
neurons overexpressing SNCA through endocytosis, resulting in Lewy
body formation (Desplates et al. 2009). Interestingly in co-culture,
astrocytes (glial cells sharing a common lineage with oligodendrocytes)
were shown to take up SNCA secreted by neurons, resulting in an
inflammatory response by the astrocytes (Lee et al. 2010). Microglia
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were also shown to take up SNCA through receptor-mediated
endocytosis (Lee et al. 2008).
To date, no studies have examined if a PD familial variant of
SNCA, such as A53T, is taken up by oligodendrocytes. However, A53T
and other synuclein fibrils have been shown in PD models to form
inclusion bodies and induce apoptosis (Parihar et al. 2008, Kragh et al.
2009). Thus, my first objective was to determine if C6
oligodendrocyte-like cells take up SNCA Wild Type (WT) and/or a PD
familial mutant, SNCA A53T. Protein uptake was measured using
western blot analysis of protein from cells treated with two
concentrations of SNCA WT or A53T for 4 days.
My second objective was to determine if the amount of SNCA
provided in media results in a change in the quantity of SNCA taken up
by C6 cells. To evaluate protein uptake, cells were treated using 5
increasing concentrations of SNCA for 2 and 4 days. Following
treatment, protein was extracted from C6 cells and analyzed for SNCA
using western blot.
As discussed above, other studies have shown that glial cells can
take up SNCA through endocytosis. SNCA taken up by C6 cells should
induce changes in expression of a range of proteins inside the cell. If
SNCA is taken up in C6 cells in a dose-dependent manner, then
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proteins known to associate with SNCA should also change in a dosedependent manner.
To confirm that SNCA has an effect on C6 cells, a protein known
to act as a chaperone for SNCA and occurring in GCIs of MSA was
evaluated for changes in expression. Heat Shock Cognate 70 (HSC70)
is a constitutively expressed heat shock protein found to occur in GCIs
of MSA patients (Kawamoto et al. 2007). It binds with LAMP2A to
promote chaperone-mediated autophagy of SNCA (Cuervo et al.
2004). Downregulation of the HSC70 gene expression has also been
correlated with SNCA aggregates in the pons of MSA patients
(Langerfield et, al 2007). Thus HSC70 protein expression was
evaluated using western blot analysis of protein from C6 cells treated
for 2 and 4 days with 5 increasing concentrations of SNCA.
Methods
Preparation of C6 oligodendrocyte cultures
C6 rat glioblastoma cells obtained from ATCC (CCL-107™) were
cultured in RPMI 1640 media (GIBCO©). Synuclein stocks were
created from lyophilized protein (Sigma-Aldrich©). To induce an
oligodendrocyte-like phenotype, 5 µl of retinoic acid (RA) from a stock
solution (1 µg RA / 1ml 95% EtOH) was added to flasks for each ml of
media (retinoic acid induces Myelin Proteolipid Protein in C6 cells
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resulting in oligodendrocyte-like cells (Lopez-Barahona et al. 1993,
Zhang et al. 2001).
Confirmation of Oligodenrocyte-like cells
To confirm retinoic acid inducement of the oligodendrocyte
marker Mylein Basic Protein (MBP), C6 cells were treated with RA in
culture for 4 days and examined using Immunocytochemistry
methods. Briefly, following treatment cells were washed with Ca, Mgfree tyrodes solution, and fixed for 4 hours in Bouin’s solution. After
fixation, cells were washed in 70% EtOH to remove the Bouin’s
solution. Cells were then washed 3 times with Tris-buffered saline, TBS
(pH 7.2-7.4) and treated with 3% normal mouse serum (NMS) in TBS
for 1 hour to inhibit cross reactivity of the secondary antibody. After
blocking, cells were treated overnight with 1:500 Rabbit anti-MBP
(Sigma-Aldrich) antibody. The following day, cells were washed 3
times with TBS and treated with biotinylated mouse anti-rabbit
secondary (Chemicon) at a concentration of 1:200 for 30 minutes.
Next cells were washed 3 times in TBS and labeled using the
Vectastain ABC-AP kit (Vector©) with Vector© Red substrate per the
manufacturer’s protocol.
Following staining, cells were coversliped and 4 fields (40x
objective, 352 µM x 276 µM) per sample were photographed using a
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Spot Cooled Color Digital Camera (Diagnostic Instruments, Inc,
Sterling Heights, Mi) attached to a Nikon Eclipse E600 Microscope. The
area of staining in cells was measured using ImageJ (nih.gov).
Stained area was selected using the color deconvolution macro in
ImageJ. The selection was then converted to a pure black and white
image using the threshold tool. Total area stained was then
measured. The same process was used to select for total cellular area.
The percent of area stained in cells was then analyzed using a t-test
from the statistical program Statview (version 5, from SAS institute).
Analysis revealed that Retinoic Acid was shown to induce increased
expression of MBP (Figure 1).
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Figure 1. MBP staining in C6 cells treated with Retinoic Acid. A. RA-treated Cells B.
Non-treated cells. C. No primary antibody. Cells treated with retinoic acid had a
significantly higher expression of MBP protein. RA treated cells had staining for MBP
in approximately 66 percent of the total cellular area in culture. RA- cells had MBP
staining in approximately 34 percent of the total celluar area (p=0.027, standard bar
= 20 µm, error bars = 1 S.E.)

Western Blot Analysis
Cells were extracted in RIPA buffer with protease inhibitor
cocktail (Sigma ©). The concentration of extracted protein was
calculated using a Bradford assay. Ten micrograms of protein was run
with 4-20% NuPAGE® Tris glycine gels with NuPAGE® SDS running
buffer per the manufacturers protocol (Invitrogen©). Briefly using the
Bradford assay, samples were loaded into microtubes with 2 µl of
reducing agent and 5 µl of 4x SDS glycine running buffer. Finally the
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total volume in the micro tube was brought to 15 µl using dH20. After
electrophoresis, protein was transferred for 2 hours to using NuPAGE®
Tris-glycine transfer buffer onto nitrocellulose blot paper
(Invitrogen©). Protein was resolved using a Western Breeze© kit per
manufacturers protocol, with rabbit anti-SNCA antibody (Sigma ©) at
1:1000, or goat anti-HSC70 (Santa Cruz ©) at 1:500.
Statistics and Image Analysis
The nitrocellulose blots were scanned and saved in JEPG format.
Band intensity was analyzed using ImageJ (nih.gov) gel measuring
function. Statistics for the average area were calculated using
Statview version 5 software, from SAS institute, using an ANOVA
comparison.
Results
C6 cells take up extracellular SNCA
To determine if cells would take up SNCA, C6 cells were treated
with SNCA WT or SNCA mutant A53T for 4 days. Using western blot
analysis, protein extracted from C6 cells showed that both SNCA WT
and A53T protein were taken up by C6 cells (Figure 2). Additionally
truncated forms of the proteins were found for both types of SNCA
after uptake. The stock bands for SNCA WT and A53T occur at an
apparent molecular weight of 17 kDa. A second band found in C6 cell
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extracts, was detected at 15 kDa below the typical band. The uptake
of SNCA WT and A53T in C6 cells were not significantly different from
each other (Figure 2).

Figure 2. Western Blot anti-SNCA A. Synuclein standard 0.325 µg, B. Untreated
Cells, C. 2 µg/ml SNCA WT, D. 12 µg/ml SNCA WT, E. 2 µg/ml A53T, F, 12 µg/ml
A53T. Additional lanes are SeeBlue® Plus2 protein standard for Myoglobulin Red,
Lysozyme and Aprotinin. SNCA and A53T bands occur at an apparent molecular
weight of 17 kDa, with a second band detected at 15 kDa below the typical band (A).
Uptake of wild type versus mutant (A53T) SNCA by C6 cells was not significantly
different for both bands (p=0.101) (N=4).

The next objective was to determine if SNCA uptake is
dependent on the concentration of SNCA in media and/or the duration
of exposure. C6 cells were treated with SNCA at increasing
concentrations for 2 and 4 day replicates to determine if dose and time
had an influence on the uptake of the protein. For both the 2 and 4
day treatments, SNCA uptake was significantly higher in the 6, 8.5 and
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11 µg/ml treatments groups, compared to the control, 1.5 and 3 µg/ml
treatment groups (Figure 3).

Figure 3. Western Blot of C6 cells treated with SNCA for 2 or 4 days. Untreated C6
cells, 1.5 µg/ml, 3 µg/ml, 6 µg/ml, 8.5 µg/ml and 11 µg/ml SNCA). Concentrations
above 6ug/ml were statistically different from control, 1ug and 3ug/ml treatments of
SNCA for both 2 and 4 days. N=4, Error bars = 1 S.E.

Expression of HSC70 in C6 cells changes with SNCA treatment
concentration
To evaluate if SNCA induces changes in expression of proteins
known to occur in GCIs, HSC70 expression was evaluated using
western blot (Kawamoto et al., 2007). After 2 days of treatment, cells
treated with 6 µg/ml of SNCA had significantly higher expression of
HSC70 than control cells, 1.5 and 11 µg/ml treatments (Figure 4).
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Cells treated with 11 µg/ml additionally had a lower expression than
the 3 and 8.5 µg/ml treatment groups. After 4 days, cells treated with
3 µg/ml SNCA had significantly higher levels of HSC70 than the control
cells, 6, 8.5 and 11 µg/ml treatment groups.
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Figure 4. HSC70 expression after treatment with SNCA. C6 oligodendrocyte-like cells
were treated with SNCA for either 2 or 4 days. Following treatment, western blot
analysis of protein extracted from the cells showed an increase in HSC70 expression,
followed by a decrease at higher concentrations of SNCA. This occurred in both the
2 and 4 day treatments at different concentrations. N=4, Error bars = 1 S.E.

Discussion
In this study, I demonstrate that C6 oligodendrocyte-like cells
can be used as a model system for determining the effects of
exogenous SNCA on oligodendrocyte-like cells. I found for both WT
and A53T SNCA treatments appear to be taken up in a dosedependent manner. A band was detected at approximately 17 kDa that
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corresponds to the band observed when stock protein is
electrophoresed. A second band was shown to occur in protein
extracted from C6 cells at approximately 15 kDa. Inhibition of the
lysosome was shown to abolish the truncated band in one study
(Muntane et, al. 2012). This second band suggests that the protein is
taken up and modified by the C6 cells.
Truncation of SNCA has been shown to occur in Lewy bodies and
oligodendrocytes of MSA patients (Fujiwara et al. 2002, Visanji et al.
2011, Muntane et al. 2012). The apparent modification of the protein
observed in this study could be a truncated SNCA fibril resulting in a
smaller apparent molecular weight than full length SNCA (Anderson et,
al. 2006, Luk et, al. 2009, Muntane et, al. 2012). The truncated SNCA
protein could cause intercellular changes due to interaction with BAD,
PKC-delta and 14-3-3 proteins (Ostrerova et al., 1999). Additionally
overexpression of truncated SNCA has been shown to promote
aggregation of SNCA (Liu et, al. 2005, Visanji et, al. 2011).
HSC70 is a constitutively expressed protein involved in the
degradation of SNCA through the lysosome (Cuervo, et al 2004), and
has been shown in GCIs of MSA patients (Kawamoto, et al 2007). In
C6 cell studies, the highest expression of HSC70 occurred at different
concentrations depending on the amount of time cells were exposed to
SNCA. HSC70 expression was highest after treatment with 6 µg/ml
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SNCA for 2 days, compared to 3 µg/ml after 4 days of treatment. This
increase could be an example of the C6 cells attempting to cope with
the increased amount of SNCA. It has been shown that
overexpression of HSC70 can inhibit SNCA toxicity in Drosophila
(Auluck et al. 2002). However the C6 cells appear to show a reduction
in HSC70 expression. This could signify a failure of the cells to
compensate for the increased SNCA. Interestingly, a decrease in
HSC70 mRNA occurred in global gene expression measured in terminal
MSA patients (Langerveld et al. 2007).
Regulation of HSC70 expression can be achieved through several
processes. Expression can be increased with the treatment of insulin
in diabetes resulting in an activation of the AKT pathway (Chen et al.
2006). Secondly, oxidative stress has also been shown to increase
HSC70 expression as a mechanism to facilitate removal of unwanted
protein into the lysosome (Kiffen et al. 2004, Saftig et al. 2009, Li et
al. 2011). These pathways of activation could be compromised as the
level of SNCA increases resulting in a loss of HSC70 activation.
Lastly, HSC70 also functions in uncoating of clatherin-coated
vesicles (Rapoport et al. 2008). Downregulation of HSC70 prevents
clatherin removal and reduces endocytosis. This could be an attempt
by the cell to reduce uptake of SNCA by reducing endocytosis of the
protein.
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Conclusion
In conclusion, C6 cells take up SNCA when added to the media.
This uptake does not appear to be influenced by the A53T mutation
known to induce aggregation of SNCA. The amount of SNCA available
for uptake does appear to influence the amount of SNCA absorbed.
The pattern of SNCA uptake at 2 and 4 day treatments appears similar
with significant amounts of protein being absorbed at the three highest
concentrations tested.
SNCA appears to undergo a truncation when taken up by C6
cells. Truncations of 2-3 kDa smaller than full length SNCA, similar to
those observed in this study, have also been seen in other studies of
SNCA (Anderson et al. 2006, Luk et al. 2009, Muntane et al. 2012).
Truncations in these studies have been shown to be intracellular in
nature resulting in aggregated SNCA (Liu et al. 2005, Luk et al. 2009).
Due to the observation of a truncated protein in C6 oligodendrocytelike cells, this suggests that SNCA is being taken up by C6 cells.
Lastly, HSC70 is influenced by the concentration and amount of
SNCA in culture. Changes in a protein known to rescue cells from
SNCA treatment suggests C6 cells are responding to SNCA after
uptake. Interestingly time appears to influence the expression of
HSC70. At 2 days, 6 µg/ml of SNCA treatment shows high expression
of HSC70, but at 4 days of treatment C6 cells show reduced
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expression of 6 µg/ml compared to controls. If GCIs in MSA patients
represent an initial increase of HSC70 to facilitate the removal of extra
SNCA into the lysosome, then this could explain the initial increase in
HSC70 due to SNCA treatment.
Overall this model demonstrates the probability of C6
oligodendrocyte-like cells to function as a model for SNCA uptake by
oligodendrocytes in MSA. Use of this technique allows for further
examination of SNCA-induced gene and protein expression changes in
oligodendrocyte-like cells.
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CHAPTER III
SNCA INDUCES TRYPAN BLUE-DEFINED CELL DEATH AND CHANGES
IN EXPRESSION OF CASPASE 3 (A MARKER FOR APOPTOSIS)
Introduction
Programed cell death in multicellular organisms is referred to as
apoptosis. It is involved in the removal of unwanted cells during
development or from disease. Initiation of apoptotic cell death results
in chromatin condensation, chromosome fragmentation, cell blebbing
and shrinkage (Kerr et al. 1972, Savill et al. 1990, Brown et al. 2002).
The cell breaks into fragments containing the intercellular components.
Phagocytic cells then proceed to engulf these fragments clearing the
debris (Krysko et al., 2006).
Caspase 3 (CASP3) is a protease that is activated during
programed cell death (Porter and Jaenicke 1999). It is involved in the
cleavage of proteins, condensation of chromatin and DNA
fragmentation. CASP3 is expressed constitutively as Pro-Caspase 3
and is activated by proteolytic cleavage resulting in two subunits
forming an active protein.
Two types of pathways are involved in apoptosis, intrinsic and
extrinsic. Intrinsic pathways involve activation of apoptosis due to DNA
damage and mitochondrial stress. Induction of the intrinsic pathway
results in activation of CASP3 through Caspase 9. The extrinsic
pathway involves extracellular signals through the Fas Associated
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Death domain activating Caspase 8, which then activates CASP3
(Wlodkowic et al. 2011).
Trypan blue is a vital stain used for measuring viability of living
cells in culture. Living cells exclude trypan. Non-viable cells are
unable to exclude the dye and turn a blue color. To determine if SNCA,
taken up by C6 cells, results in cell death, cells were treated with
different doses of SNCA for 2 and 4 days. After treatment, cells were
treated with trypan blue, and blue cells were counted to determine the
percent of cells in culture that were non-viable.
As discussed above, CASP3 is expressed during apoptosis. To
determine if C6 cells treated with SNCA were undergoing apoptosis,
cells were treated with different doses of SNCA over 2 and 4 days.
After treatment, protein was extracted and stained via western blot for
CASP3.
Methods
Typan Blue Cell Viability Assay
As described in chapter 2, C6 cells were cultured in 24 well plates for 2
and 4 days with SNCA. After treatment, cells were washed using PBS
solution (pH 7.2-7.3) and trypsinized. After trypsin application for
approximately 30 seconds to loosen adhered cells, 1ml of stock media
was added to each well. Next, 0.1 ml of a 0.4% solution of trypan blue
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in PBS was added to each well. After 5 min of exposure to trypan blue,
10 µl of cells were added to a hemocytometer. A picture of each
quadrant on the hemocytomter was taken using a Spot Cooled Color
Digital Camera (Diagnostic Instruments, Inc, Sterling Heights, Mi)
attached to a Nikon Eclipse E600 Microscope. Cell counts were
tabulated using the cell counter tool included in the ImageJ software
package (nih.gov). Raw numbers were corrected for the dilution of
cells in each well using the equation: Number of viable cells × 104 ×
1.2 = cells/mL culture. Then the percent dead cells in culture were
calculated using the ratio of non-viable/viable cells.
Western Blot
Briefly, as described in chapter 2, C6 cells were cultured for 2 and 4
days with SNCA. After treatment protein was extracted using RIPA
buffer and electrophoresed. CASP3 protein was then resolved in
western blots using rabbit anti-active-casp3 (Sigma ©) at 1:500.
Statistics
An ANOVA comparison was used to evaluate differences in the
percentage of non-viable cells in culture as a function of SNCA
treatment. Statistics were completed using Statview version 5
software, from SAS institute. In addition the same ANOVA method
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was used to compare the differences in CASP3 western blot
expression.
Results
SNCA Induces Cell Death in C6 Oligodendrocyte-like Cells
To determine if SNCA induces cell death, cells were treated with SNCA
at different doses for 2 or 4 days. After 2 days cells treated with SNCA
at 3 µg/ml or higher had a significantly higher percentage of cell death
compared to controls (untreated cells) (Figure 5). Additionally cells
treated with 1.5 µg/ml showed significantly lower cell death than cells
treated with 6, 8.5 or 11 µg/ml. Cells treated with 3 µg/ml also
showed significantly less cell death than cells treated with 11 µg/ml.
After 4 days all treatment groups had significantly higher percentages
of cell death than controls. Cells treated with 1.5 µg/ml showed
significantly less cell death than 8.5 and 11 µg/ml treatment groups.
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Figure 5. Trypan Blue Cell Counts. C6 cells were treated with SNCA for 2 or 4 days.
After treatment, the percentage of non-viable cells was measured using Typan Blue
staining. The percentage of cells undergoing cell death in culture. After 2 days of
treatment, 3, 6, 8.5 and 11 µg/ml treatment groups were significantly higher than
control cells and cells treated with 1.5 µg/ml SNCA (a). Additionally cells treated
with 11 µg/ml had significantly higher cell death than the 3 or 8.5 µg/ml treatments
(b). After 4 days of treatment all treatments had significantly higher cell death than
controls (c). Additionally, cells treated with 6, 8.5 and 11 µg/ml had significantly
higher cell death than 1.5 µg/ml treated cells (d). N=4 Error Bars = 1 S.E.

SNCA Induces Changes in Caspase 3 Expression in C6
Oligodendrocyte-like Cells
To determine if cells were undergoing apoptosis, an antibody to
active Caspase 3 was used to stain for the CASP3 Protein in western
blots. After 2 days of treatment, cells treated with 6 µg/ml SNCA had
significantly higher expression of CASP3 than control cells and 1.5
µg/ml SNCA treated cells (Figure 6). Additionally cells treated with 11
µg/ml SNCA of had higher expression of CASP3 than controls. All other
groups showed a trend to higher expression of CASP3, although not
significantly. In contrast, after 4 days, the lower dosage group treated
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with 1.5 µg/ml SNCA had significantly higher expression of CASP3 than
control, 8.5 and 11 µg/ml SNCA groups. Additionally cells treated with
8.5 µg/ml SNCA were significantly lower than 3 or 6 µg/ml treatments.

Figure 6. Caspase 3 protein expression after treatment with SNCA. C6 cells were
treated with SNCA for 2 or 4 days. After 2 days, C6 cells treated with SNCA showed
significantly increased expression of CASP3 protein with 6 and 11 µg/ml treatments,
compared to controls (a). Casp3 protein expression was also higher in cells treated
with 6 µg/ml SNCA compared to the 1.5 µg/ml treatment (b). After 4 days, C6 cells
treated with 1.5 µg/ml SNCA showed an increase in CASP3 expression compared to
control cells and cells treated with 8.5 or 11 µg/ml SNCA (c). In addition, cells
treated with 3 and 6 µg/ml had significantly higher CASP3 expression than cells
treated with 8.5 µg/ml SNCA (d). N=4, Error bars = 1 S.E.
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Discussion
SNCA causes cell death in a dose-dependent manner of C6
oligodendrocyte-like cells after treatment. At 2 days, cells treated with
3 µg/ml SNCA had a significantly higher percent of dead cells in
culture than controls. Cells treated with 1.5 µg/ml SNCA however were
not significantly different from controls. After 4 days of treatment, the
cell death threshold appears to shift to a lower concentration. Cells
treated with 1.5 µg/ml SNCA for 4 days had a significantly higher
percent of dead cells in culture.
This suggests that the uptake of SNCA may not be the only
regulating factor of apoptosis. Phosphorylation of SNCA at Ser-129
(Visanji et, al. 2011), or truncation of SNCA described in chapter 2,
could induce changes to protein-protein interactions of SNCA with
PLD2, BAD, 14-3-3, PKC-Delta (Jenco et al., 1999, Ostrerova et al.,
1999, Bennett et al., 1998). These changes could result in a feedback
loop of the IRS/PI3K/pAKT pathways resulting in a decrease proapoptotic factors BAD and Caspase 9 (Tiwary et al., 2011).
Cells treated with a lower dose of SNCA may need more time to
accumulate SNCA inside the cell, to induce cell death. This would
account for the lower dose group of 1.5 µg/ml SNCA having a
significant difference from controls only after 4 days of treatment.
Secondly the rate of cell death appears to be constant for the higher
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dose groups. If more SNCA was required to induce cell death, it would
be expected that SNCA at 8.5 or 11 µg/ml SNCA would increase the
number of dead cells from 2 to 4 days.
Conclusion
SNCA induces cell death in C6 cells in a dose-dependent manner.
Cells treated with SNCA at higher concentrations had significantly
higher cell death than lower concentrations of treatment. This
occurred at both 2 and 4 days of treatment.
After 2 days, SNCA induced an increased Caspase 3 expression
in the 6 and 11 µg/ml treatment groups. However Caspase 3
expression after 4 days of treatment was highest in cells treated with
1.5 µg/ml SNCA. This also is reflected in the typan blue result where
after 2 days of treatment, cell death at 1.5 µg/ml was insignificant.
Then after 4 days of treatment cell death increased in this group
resulting in a significant amount of apoptosis compared to control
cells.
However, these results have some contradiction between the
rate at which cells die and the expression of CASP3. After 2 days of
treatment tyrpan blue staining and CASP3 expression are elevated due
to SNCA. After 4 days of treatment CASP3 expression is increased in
the lower concentration groups, but decreased in cells treated with the
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higher concentrations of SNCA. HSC70 and/or other chaperone
proteins could be reducing the amount of CASP3 expression.
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CHAPTER IV
SNCA INDUCES CHANGES IN MESSENGER RNA EXPRESSION IN C6
OLIGODENDROCYTE CELLS, SUGGESTING NEW TARGETS OF
INTEREST FOR STUDY IN MSA
Introduction
DNA microarrays are a genomics tool that allows for rapid
screening of a sample for a large number of changes in gene
expression. Oligonucleotides corresponding to specific genes are
adhered to a fabricated chip (Maskos and Southern 1992). Samples of
mRNA isolated from cellular tissue are hybridized to the chip and read
with a laser scanner to evaluate expression of mRNA (Langerveld et
al., 2007).
DNA microarrays have been used in many neurological studies
of diseases (Mandel et al., 2003). Samples of mRNA have been taken
from blood and brain cells of deceased patients (Glatt et al., 2005).
Samples have also been taken from mouse models of disease (Bonin
et al., 2004) and tissue culture models (Dimcheff et al., 2006).
Microarrays have also been useful in identifying genes previously
unknown in MSA. Nineteen genes related to apoptosis had changes in
expression in blood samples, including a regulator of HSC70 discussed
in chapter 2 (Ide et al., unpublished data). In a DNA microarray study
of human pons tissue, four other genes related to apoptosis were also
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identified (Langerveld et, al. 2007). Additionally, HSC70 was also
found to be down-regulated and correlated with SNCA expression in
the white matter tracts of the pons.
However, in evaluating the gene expression in patients with
MSA, correlating the amount of SNCA influencing mRNA expression is
not easily accomplished. With whole tissue, such as blood or sections
of brain, the composition of the sample has a mixture of cell types.
Thus, DNA microarray analysis of C6 cells was used in this study to
better understand if SNCA could influence gene expression specifically
of oligodendrocyte-like cells.
As such, C6 cells were treated with SNCA for 4 days, and mRNA
was extracted and analyzed for changes in gene expression. To follow
up on genes identified by the array, one gene of interest, Hook
Homolog 3 (HOOK3) was evaluated using western blot of C6
oligodendrocyte-like cells treated with SNCA for 2 or 4 days at
increasing concentrations.
Methods
DNA Microarray
As previously described in chapter 2, a control and two
treatment groups (5 and 10 µg/ml SNCA) of C6 cells were grown for 4
days. After 4 days, total RNA was isolated from C6 tissue using
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Qiagen RNEasy Mini kits following the manufacturer’s protocol (Qiagen,
Valencia, CA).
Extracted RNA was analyzed for purity by calculating the
absorbance ratio of A260/A280. RNA was also electrophoresed to
ensure quality of the sample through examination of the 28S and 18S
ribosomal bands. Having passed these checks, samples were
hybridized to Affymetrix Rat 230 2.0 DNA microarrays per
manufacturer’s protocol using an aliquot containing 5 μg RNA.
Arrays were evaluated using the Gene Array Scanner (Agilent
Technologies). Expression of each gene was measured using
Affymetrix Microarray Suite v5.0. Gene expression differences were
analyzed using a t-test between either control vs 5µg/ml or control vs
10µg/ml treated cells (p-value < 0.05). All genes reported were
selected using a cut-off criteria of 1.41 fold change from control cell
gene expression.
Western Blot
As described in chapter 2, C6 cells were treated with SNCA for 2
and 4 days at increasing concentrations of 0, 1.5, 3, 6, 8.5 and
11µg/ml. Following treatment, protein was extracted and
electrophoresed for western blot. HOOK3 protein was resolved using
goat anti-HOOK3 (Santa Cruz ©) at 1:500.
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Results
DNA microarray analysis shows changes in gene expression with
treatment with SNCA
To evaluate changes in cell response, cells were treated with
either 5 or 10 µg/ml SNCA for 4 days and expressed RNA was
extracted for Affymetrix gene chip analysis (Table 1 & 2). Microarray
analysis shows that several structural and metabolic genes were
influenced by treatment. The highest fold change was found in the
downregulation of Echinoderm microtubule associated protein like 4
(EML4) at the 10 µg/ml treatment. HOOK3 had the next greatest fold
change difference and was downregulated at the 5µg/ml treatment.
Interestingly the only three genes that were upregulated in either
treatment of SNCA have links to apoptosis in other models. Tubby
mouse homolog (TUB) was upregulated at 5 µg/ml. Insulin receptor
substrate 2 (IRS2) and v-erb-b2 erythroblastic leukemia viral
oncogene homolog 3 (ERBB3) were upregulated at 10 µg/ml.
Using the DAVID bioinformatics resource database (Huang et, al
2009), the genes listed in table 1 and 2 were compared for similarities
in GO function annotation. IRS2, NIFA, TUB and ERBB3 were classified
as being a response to organic substance. Additionally, IRS2 and
ERBB3 were also regulators of glucose import. HOOK3, PTPN4 and
ARPC5L were classified as having cytoskeletal protein binding function.
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RAD18, GPD2, PRPS2, ZFP-62 and ZFP131 were classified as having
cation binding properties. PRPS2, SMC4 and ERBB3 were classified as
having Nucleotide binding function. GPD2, PTPN3 and ERBB3 are also
classified in phosphate metabolic processing. RAD18, PTPN3, ARPC5L
and SMC4 have association with non-membrane-bounded organelles
consisting of ribosomes and cytoskeleton.
DAVID only identified one disease common to the genes
discussed in tables 1 and 2. ERBB3, IRS2 and GPD2 have a
relationship with noninsulin-dependent, type 2 Diabetes mellitus.
THOC2, EML4 and ANKRD11 were not reported as having similar
function to any other genes reported. THOC2 is a component of the
THO Complex that binds with mRNA post translation. ANKRD11 is a
nuclear receptor substrate that modifies microtubules to become
longer and more dynamic.
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Table 1. DNA microarray analysis of C6 cells treated with 5 µg/ml SNCA for 4 days.
Genes listed were statistically different from controls in treated cells (p<0.05).
5 µg/ml SNCA Treated Cells vs Control Cells
Gene Symbol

Probe Set ID

Tub

1369283_at

Nfia

1369679_a_a
t
1375562_at

Prps2

1398262_at

RGD1560191

1379029_at
1379130_at

Smc4

1383008_at

Hook3

1385931_at

Thoc2

1386525_at

Ptpn4

1391757_at

Rad18

1392449_at

Zfp131

1395418_at

RGD1560191

1396175_at

Fold
Change
1.454974
5
1.509205
7
1.492197
5
1.514701
4
1.651205
8
1.539181
5
1.500074
5
1.739286
3
1.410694
2
1.426900
3
1.477326

Regulation

Gene Title

up

tubby homolog (mouse)

down

nuclear factor I/A

down

Transcribed Locus

down

phosphoribosyl pyrophosphate
synthetase 2
similar to Zinc finger protein 62
homolog (Zfp-62) (ZT3)
Transcribed Locus

1.475377
6
1.426784
3

down
down
down
down

structural maintenance of
chromosomes 4
hook homolog 3 (Drosophila)

down

THO complex 2

down
down

Protein tyrosine phosphatase,
non-receptor type 4
RAD18 homolog (S. cerevisiae)

down

zinc finger protein 131

down

similar to Zinc finger protein 62
homolog (Zfp-62) (ZT3)
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Table 2. DNA microarray analysis of C6 cells treated with 10 µg/ml SNCA for 4 days.
Genes listed were statistically different from controls in treated cells (p<0.05).
10 µg/ml SNCA Treated Cells vs Control Cells
Gene Symbol

Probe Set ID

Fold Change

Regulation

Gene Title

Erbb3

1369088_at

1.4367973

up

Irs2

1397999_at

1.5204533

up

v-erb-b2 erythroblastic
leukemia viral oncogene
homolog 3
Insulin receptor substrate 2

Nfia

1369679_a_a
t
1375562_at

1.5183513

down

nuclear factor I/A

1.5751356

down

Transcribed locus

Arpc5l

1375641_at

1.482691

down

Eml4

1378016_at

1.8409163

down

Gpd2

1387670_at

1.4769446

down

Prps2

1398262_at

1.5108037

down

RGD1560191

1379029_at

1.4957618

down

1381619_at

1.5083959

down

actin related protein 2/3
complex, subunit 5-like
echinoderm microtubule
associated protein like 4
glycerol-3-phosphate
dehydrogenase 2,
mitochondrial
phosphoribosyl pyrophosphate
synthetase 2
similar to Zinc finger protein
62 homolog (Zfp-62) (ZT3)
Transcribed locus

Ankrd11

1381809_at

1.7838049

down

ankyrin repeat domain 11

Smc4

1383008_at

1.5097065

down

Rad18

1392449_at

1.5074692

down

1395368_at

1.4257778

down

structural maintenance of
chromosomes 4
RAD18 homolog (S.
cerevisiae)
Transcribed locus

1396175_at

1.4594721

down

RGD1560191

similar to Zinc finger protein
62 homolog (Zfp-62) (ZT3)

Expression of HOOK3 in C6 cells decreases with the treatment of SNCA
To determine if changes in gene expression are reflected in
protein expression, HOOK3 was evaluated using western blot after 2
and 4 days of treatment with increasing concentrations of SNCA. After
2 days of treatment, control cells and 3 µg/ml treated cells had
significantly higher expression of HOOK3 than 11 µg/ml treated cells.
After 4 days of treatment, control cells had significantly higher
expression of HOOK3 than all treatment groups. Additionally, cells
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treated with 1.5 and 3 µg/ml SNCA had significantly higher expression
than 11 µg/ml treated cells.

Figure 7. HOOK3 expression in C6 cells treated with SNCA. Cells were treated with
SNCA for 2 or 4 days. Both treatments showed a decrease in HOOK3 protein
expression. After 2 days only cells treated with 11 µg/ml were significantly lower in
HOOK3 protein expression. However, after 4 days, all cells treated with SNCA had
significantly lower HOOK3 expression than controls. In addition cells treated with 11
µg/ml showed significantly lower expression than 1.5 and 3 µg/ml treatments. N=4,
Error bars = 1 S.E.
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Discussion
Changes in gene expression can be induced by treatment with
exogenous SNCA. HOOK3, a member of the Hook family, binds to
microtubles and Golgi (Walenta et al., 2001), is involved in protein
endocytosis, clearing of macrophage scavenger receptors (MSR1)
(Sano et al., 2007), and interacts with an apoptosis regulating gene
(AKTIP) (Xu et al., 2008). Western blot analysis of HOOK3 showed a
decrease in protein expression with treatment of SNCA at both 2 and 4
days. HOOK3 decrease appears to be greater at 4 days. This supports
the DNA microarray data collected from the C6 cells showing a
decrease in gene expression after 4 days of treatment. Interestingly,
in a neural cell model testing the effect of prefibrillar SNCA, the Golgi
was shown to become fragmented (Gosavi, et al., 2002). Due to the
relationship HOOK3 has with SNCA this could explain the change in
expression.
Several other genes of interest were identified using DNA
microarray. Microtubule-related genes, EML4 and ARPC5L, were
downregulated in the 10 µg/ml treatment. SNCA has been shown to
interact with tubulin and other microtubule proteins (Alim et al.,
2002). EML4 is responsible for stabilization of microtubules and
influence growth rates in cells (Houtman et al., 2007). ARPC5L is
believed to have similar functionality to ARPC5 as part of the actin 2/3
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complex in regulation of actin polymerization (Humphray et al., 2004).
Finally, TUB was upregulated in the 5 µg/ml treatment but not at 10
µg/ml. Interestingly TUB has been shown to interact with MAP1A
(microtubule-associated protein 1A) a protein commonly found in
protein aggregates (Ikeda et al., 2002).
Upregulation of Erbb3 has been shown to be involved in C6
oligodendrocyte survival as a receptor of neuregulins (Flores et al.,
2000). Deactivation of ERBB3 has been shown to inhibit apoptosis
(Sithanandam et al., 2005). ANKRD11, which has been shown to
coactivate P53 in breast cancer (Neilson et al., 2008), was shown to be
downregulated at 10 µg/ml. Interestingly P53 has been shown to occur
in many neurological diseases resulting in apoptosis, including MSA (de
la Monte et al., 1998). IRS2, shown to inhibit apoptosis (Ueno et al.,
1999, Lingohr et al., 2003), was upregulated at 10 µg/ml.
Many genes of interest also have relationships with the PI3K-AKT
pathway. ERBB3 has been shown to activate the PI3K-AKT pathway
(Soltof, et al., 1994, O’Merra et al., 2011). IRS2 has also been shown
to regulate the expression of the AKT pathway (Russo et al., 2007)
Additionally, HOOK3 interacts with AKT through the FTS/HOOK/
p107FHIP complex (FTS is also called AKTIP).
It is possible that the cells are attempting to cope with the
increased SNCA. The changes in gene expression of ERBB3 IRS2 and
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ANKRD11 suggest an inhibition apoptosis. In the previous chapter we
see CASP3 apoptosis peaks in expression at different concentrations
based on the concentration of treatment. This could be explained by
the increased expression of ERBB3, IRS2 and the decrease in
ANKRD11 if they are playing a role in regulating apoptosis.
Conclusion
Cells treated with SNCA appeared to undergo changes in gene
expression. In cells treated with 5ug/ml SNCA, 1 gene was
upregulated and 12 genes were downregulated. In cells treated with
10ug/ml SNCA, 2 genes were upregulated and 13 genes were
downregulated. Many of these genes are related to microtubules,
apoptosis and/or AKT.
To test if changes in gene expression match protein expression,
C6 cells were treated with SNCA at increasing concentrations and
evaluated via western blot analysis for HOOK3 protein. After 2 days of
treatment with SNCA, HOOK3 protein showed a decrease in expression
at the highest concentration of SNCA. After 4 days of treatment with
SNCA, HOOK3 protein showed a decrease in expression at all
concentrations of treatment. This result confirms the decrease in gene
expression of HOOK3 observed in the DNA microarray.
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CHAPTER V
TWO PROTEINS INVOLVED IN APOPTOSIS, PROGRAMMED CELL DEATH
4 AND FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER B, APPEAR
TO BE MARKERS IN MULTIPLE SYSTEM ATROPHY
Introduction
As discussed in chapter 3 CASP3, a marker for apoptosis,
showed changes in expression due to the treatment with SNCA. Based
on these data, I next wanted to determine if apoptotic-related genes
previously identified using DNA microarrays, could be influenced by
treatment with SNCA. Microarrays have also been useful in identifying
genes previously unknown in MSA. Nineteen genes related to
apoptosis had changes in expression in blood cells of MSA patients
compared to controls (Ide et al., unpublished data). In a DNA
microarray study of human tissue, four other genes related to
apoptosis were also identified (Langerveld et, al. 2007).
Programmed Cell Death 4, PDCD4 had upregulated expression and was
associated with the amount of misfolded SNCA in brains of patients
with MSA (Langerveld et al, 2007). PDCD4 is a tumor suppressor gene
that binds to eukaryotic translation initiation factor 4 alpha (EIF4A),
and is thought to play a role in apoptosis (Lankat-Buttgereit and Göke
2003). TGF-B1 has been shown to induce PDCD4 apoptosis through
the Smad Pathway (Nakashima et al., 2009). It is regulated through
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the expression of cytokines IL-2 and IL-12 secreted by T-cells and
Natural killer cells (Azzoni et al, 1998).
PDCD4, in addition to interacting with EIF4A, has some sequence
homology with eukaryotic translation initiation factor 4 gamma
(EIF4G). This results in regulating how EIF4G functions in transporting
RNA to the ribosome for translation (Yang, et al, 2003; Suzuki, et al,
2008). This interaction inhibited CAP-dependent translation of protein
in cells (Jansen et al., 2005). PDCD4 has also been shown to shuttle
between the cytoplasm and nucleus when bound to RNA suggesting a
role in cell growth and transformation (Bohm et al., 2003).
A second gene of interest, the killer cytokine, pancreatic-derived
factor (FAM3B) was upregulated in the blood of MSA patients (Ide et
al, in preparation). FAM3B was shown to induce apoptosis in
pancreatic β-Cells (Cao, et al, 2003). FAM3B has also been shown to
induce apoptosis in SH-SY5Y neuroblastoma cells (Narayan et al.,
2006).
This experiment had three objectives. First, to determine if these
two proteins are influenced by SNCA treatment, I treated C6
oligodendrocyte-like cells for 2 and 4 days with SNCA. Following
treatment, protein was extracted and analyzed using western blot
analysis. The second objective was to confirm that oligodendrocytes
express Caspase 3 in patients with MSA. Using immunocytochemistry,

47

sections of cerebellar tissue from MSA patients and controls were
double labeled for CASP3 and myelin basic protein (MBP), a marker of
oligodendrocytes. Lastly, to determine if FAM3B and PDCD4 are
expressed in MSA, sections of cerebellar tissue from the brains of MSA
patients and controls were evaluated using immunocytochemistry to
determine if these two proteins co-localized with MBP.
Methods
Western Blot
Briefly, as described in chapter 2, C6 cells were cultured for 2 and 4
days with SNCA. After treatment protein was extracted using RIPA
buffer and electrophoresed. FAM3B protein was resolved in western
blots using rabbit anti-FAM3B (Santa Cruz©) at 1:500. PDCD4 protein
was resolved in western blots using rabbit anti-PDCD4 (Santa Cruz©)
at 1:500.
Immunocytochemistry
Human cerebellum slides were obtained from the New York Brain Bank
at Columbia University. Slides were de-paraffinized and rehydrated
using a series of xylene and alcohol washes followed by TBS. Next
heat antigen retrieval was used to unmask proteins. Slides were
placed in 10mM Sodium Citrate buffer (pH 6.0) for 40 min at 80 ºC.
After antigen retrieval slides were washed in 3% H2O2 for 5 min
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followed by and two washes in TBS. Slides were next blocked for 1
hour in 3% normal goat serum. After blocking slides were incubated
at 4 oC overnight in either rabbit anti-FAM3B (Santa Cruz©) at 1:50,
rabbit anti-PDCD4 (Santa Cruz©) at 1:50 or rabbit anti-CASP3
(Sigma©) at 1:100. Slides were then washed in TBS and incubated in
biotinylated goat anti-rabbit secondary antibody (Santa Cruz©) at
1:100 for 30 min. Slides were then washed three times in TBS. To
detect biotin labeled secondary, a Vector ABC-DAB kit was used
following the manufactures protocol (Vector© Labs). Slides were
washed three times in TBS. DAB substrate was added to Tris-HCl
buffer (pH 7.5) and placed on slides for 10 min. Next to double label
MBP, slides were rinsed in dH20 and washed three times in TBS. Slides
were next blocked for 1 hour in 3% normal goat serum. After blocking
slides were incubated at 4 oC overnight in anti-MBP at 1:50 (Santa
Cruz©). Slides were then washed in TBS and incubated in biotinylated
goat anti-rabbit secondary antibody (Santa Cruz©) at 1:100 for 30
min. Slides were then washed three times in TBS. To detect biotin
labeled secondary, a Vector ABC-AP kit was used following the
manufacturer’s protocol (Vector© Labs). This was followed by Vector©
AP substrate kit using manufactures protocol (Levamasole (Vector)
was added to quench endogenous AP per the manufacturer’s
recommendations). Slides were washed three times in TBS then rinsed
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in H20 and counterstained for 1 min in Hematoxylin 1 (ThermoFisher).
Next slides were rinsed in H20 and placed in clarifier (ThermoFisher)
for 1 min. Slides were rinsed in H20 for 30 seconds with agitation, and
then placed into bluing agent (ThermoFisher) for 1 min. Slides were
then washed for 1 min in H20 and dehydrated through a series of
xylene-alcohol washes and cover slipped using Permimount
(ThermoFisher).
Photographs were taken using the Spot Cooled Color Digital
Camera system as described in chapter 2. Image analysis for DAB
(brown) and AP (red) were completed using the ImageJ (nih.gov) color
deconvolution tool.
The color deconvolution tool uses red, green, and blue (RGB)
vectors input by the user to differentiate between red and brown
colors. To establish these vectors I first used two images with singly
labeled cells stained either with DAB or AP. Next I selected color
deconvolution in ImageJ followed by the (Region of Interest) ROI
function to measure and save the RGB vectors. After saving these
vectors I opened the image of interest and selected the user input
function in color deconvolution to input the RGB vectors from the
single-labeled cells. After the function processed, red and brown colors
were separated by the program into new images.
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These images were then changed to 8-bit greyscale, and the
threshold tool was used to convert the image to pure black and white.
Using these images, I selected analyze particles in ImageJ and
measured the amount of area stained in pixels. The area of stain was
then converted to percent of the total area of interest. A t-test was
then completed on this data using Statview 5.0 (version 5, from SAS
institute).
Results
Expression of PDCD4 in C6 cells decreases with SNCA treatment
To determine if PDCD4 expression is influenced by SNCA
treatment, cells were grown for 2 or 4 days and evaluated using
western blot. After 2 days, cells treated with 6 µg/ml had significantly
higher expression than control cells. After 4 days, cells treated with 3
µg/ml had significantly higher expression than controls, 6, 8.5 and 11
µg/ml groups. Cells treated with 1.5 µg/ml had significantly higher
expression than 6, 8.5 and 11 µg/ml groups. Control cells also had
significantly higher expression than 8.5 µg/ml treated cells.
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Figure 8. PDCD4 expression after treatment with SNCA. After 2 days, 6 µg/ml was
significantly higher than control cells (a) (p=0.0219). After 4 days, control cells were
significantly higher than 8.5 µg/ml (b) (p=0.042). Cells treated with 1.5 µg/ml were
significantly higher than 6, 8.5 and 11 µg/ml (c) (p=0.049, <0.001, 0.006). Cells
treated with 3 µg/ml were significantly higher than controls, 6, 8.5 and 11 µg/ml
groups (d) (p=0.023, 0.018, <0.001, 0.002). N=5, Error bars = 1 S.E.

Expression of FAM3B in C6 cells decreases with the treatment of SNCA
To determine if the cytokine FAM3B is influenced by treatment
with SNCA, cells were grown for 2 or 4 days and evaluated using
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western blot. After 2 days, cells treated with 1.5, 3, and 6 µg/ml had
significantly higher expression than control cells. Cells treated with 6
µg/ml were also significantly higher than the 11 µg/ml treatment.
After 4 days, cells treated with 3 µg/ml had significantly higher
expression of FAM3B than the 8.5 or 11 µg/ml treatments.
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Figure 9. FAM3B expression after 4 days of treatment with SNCA. After 2 days, 1.5,
3 and 6 µg/ml treatments were significantly higher than control cells (a) (p= 0.02,
0.03, 0.012). Additionally, 6 µg/ml was significantly higher than 11 µg/ml (b)
(p=0.038). After 4 days 8.5 and 11 µg/ml were significantly lower than 3 µg/ml
treatment (c) (p=0.023, 0.049). N=5, Error bars = 1 S.E.
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Caspase 3 Co-localizes in the White Matter Tracts of MSA Patients
Caspase 3 (CASP3) a marker for apoptosis was also shown to be
induced due to SNCA treatment (Chapter 3). To determine if CASP3 is
expressed in oligodendrocytes of MSA patients, CASP3 was double
labeled with MBP using ICC methods. Control patients expressed little
active-CASP3 staining (2.3% of the total area) (Figure 1a). MBP
staining was uniform through the white matter tracts (40.6% of the
total area) (Figure 1b). In MSA patients, CASP3 staining increased to
17.5% of the white matter tract area and co-localized with MBP
(Figure 1c). In addition, MBP staining appears to fragment in MSA
patients. Staining of MBP decreased to 25.9% of the white matter tract
area (Figure 1d). The area of cells double labeled with CASP and MBP
increased from 0.1% in controls to 2.0% in MSA patients.

55

Figure 10. CASP3 immunocytochemistry of the white matter tracts in MSA patients.
Red = MBP, Brown = CASP3. A. Control patient sections stain for background CASP3
expression in 2.3% of the total area. B. No apparent loss in MBP staining occurs in
the white matter tracts of control patients. C. Staining of CASP3 increases in MSA
patients to 17.5% of the area stained (p<0.001). D. MBP staining appears to double
label with the fragmented CASP3. MBP showed a 14.7% decrease in the area stained
(p=0.036) Lastly double labeled tissue for CASP3 and MBP increased from 0.1% in
controls to 2.0% in MSA patients (p=0.012). N=5, Error Bars = 1 S.E
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FAM3B Co-localizes in the White Matter Tracts of MSA Patients
To determine if FAM3B is present in MSA, tissue from patients
and controls were evaluated using ICC methods. In control patients
MBP was shown to stain uniformly in the white matter tracts (52.4% of
the white matter tract area) (Figure 2a), while FAM3B did not appear
to be highly expressed (2.5% of the area) (Figure 2c). In MSA patients
MBP shows a fragmented pattern of staining and decreases to 29.2%
in the white matter tracts (Figure 2b). FAM3B also showed a
fragmented pattern of staining, that increased to 15.2% in the white
matter tracts (Figure 2d). Double labeling of MBP and FAM3B increased
from 0.7% in control patients to 7.7% of the total white matter tracts
in MSA patients.
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Figure 11. FAM3B immunocytochemistry of the white matter tracts in MSA patients.
Red = FAM3B, Brown = MBP, Blue = Counterstain. A. The area stained for MBP in
the white matter tracts of control patients appears to be uniform. B. The staining in
patients with MSA shows fragmentation of the MBP in the white matter tracts. C.
Little FAM3B staining occurs in the white matter tracts of control patients. D. FAM3B
staining appears to double label with the fragmented MBP. Image analysis showed
FAM3B staining increased from 2.5% in control patients to 15.2% of the white
matter tracts in MSA patients (p<0.001). MBP staining decreased from 52.4% in
control patients to 29.2% in of the white matter tracts in MSA patients (p<0.001).
Lastly, double labeled tissue for FAM3B and MBP increased from 0.7% in control
patients to 7.7% of the white matter tract in MSA patients (p=0.002). N=5, Error
Bars = 1 S.E.
.
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PDCD4 Co-localizes in the White Matter Tracts of MSA Patients
To determine if PDCD4 is present in MSA, tissue from patients
and controls were evaluated using ICC methods. In control patients,
MBP was shown to stain uniformly in the white matter tracts (60.45%
of the area) (Figure 3a), while PDCD4 did not stain in large abundance
(0.71% of the area) (Figure 3c). In MSA patients, MBP appeared to
increase in fragmentation with the area of MBP staining decreasing to
35.16% in the white matter tracts (Figure 3b). PDCD4 increased in
staining to 12.13% of the white matter tract. Double labeling of
PDCD4 and MBP increased from 0.45% in control patients to 4.68% of
the white matter tracts in MSA patients.
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Figure 12. PDCD4 immunocytochemistry of the white matter tracts in MSA patients.
Red = PDCD4, Brown = MBP. A. The area stained for MBP in the white matter tracts
of control patients appears to be uniform. B. Little PDCD4 staining occurs in the
white matter tracts of control patients. C. The staining in patients with MSA shows
fragmentation of the MBP in the white matter tracts. D. PDCD4 staining appears to
double label with the fragmented MBP. Image analysis showed PDCD4 staining
increased from 0.71% in control patients to 12.13% of the white matter tracts in
MSA patients (p=0.025). MBP staining decreased from 60.45% in control patients to
35.16% in of the white matter tracts in MSA patients (p=0.008). Lastly, double
labeled tissue for PDCD4 and MBP increased from 0.45% in control patients to 4.68%
of the white matter tract in MSA patients (p=0.013). N=5, Error Bars = 1 S.E.
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Discussion
It appears that exogenous SNCA can induce proteins associated
with cell death in C6 oligodendrocytes. PDCD4, FAM3B, CASP3 (shown
in chapter 3), and HSC70 (shown in chapter 2) all change in
expression due to SNCA treatment. In MSA patients, CASP3, FAM3B
and PDCD4 were shown to double-label with MBP in the white matter
tracts exiting the cerebellar folia. This corresponds to previous studies
in MSA. MSA patients with olivopontocerebellar atrophy show loss of
tissue in the white matter tracts, gliosis and axonal degeneration
(Ozawa et al. 2004, Ahmed et al. 2012). Loss of oligodendrocytes and
accumulation of GCIs in the cerebellar white matter tracts has been
shown to precede loss of neurons (Papp and Lantos 1994). Expression
of these apoptotic proteins in oligodendrocytes suggests a mechanism
for cell death, resulting in a loss of myelin that would then lead to a
loss of neurons.
As stated previously in chapter 2, HSC70 is involved with
clearing SNCA. HSC70 expression patterns are similar to CASP3,
PDCD4 and FAM3B. This suggests that the mechanism
(HSC70/LAMP2a) clearing SNCA becomes overwhelmed and is no
longer protecting the cell.
However, another possibility is that SNCA is influencing a
common pathway to PDCD4, FAM3B, CASP3 and HSC70. In the
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previous chapter, Insulin receptor substrate 2 (IRS2) was shown to be
up-regulated in C6 cells treated with SNCA. Insulin has been shown to
up-regulate expression of HSC70, preventing apoptosis (de la Rosa et
al. 1998, Chen et al. 2006). Insulin regulation of the AKT/mTOR/PI3K
pathway regulates apoptosis, survival, and homeostasis of cells
(Morgensztern and McLeoid 2005, Costa et al. 2012, Hsieh et al.
2012). Lastly, Insulin has also been shown to regulate expression of
MAPK, PKC alpha and delta, and NF-kB (Martins et al., 2010).
FAM3B appears to regulate insulin sensitivity. HepG2 liver cells
were isolated and pretreated with FAM3B. This pre-treatment reduced
the sensitivity of insulin receptor and insulin receptor substrate 1
(IRS1) to insulin (Yang et al. 2009). This inhibition also reduced
insulin-induced expression of PI3K and pAKT. In pancreatic beta cells
treated with glucose, FAM3B showed an increase in expression. When
treated with glucose and inhibitors of PI3K, CREB and PKC-alpha, all
were shown to inhibit expression of FAM3B (Wang et al. 2008). This
suggests a negative feedback loop regulating expression of PI3K and
FAM3B.
As shown in the previous chapter IRS2 was upregulated in C6
cells treated with SNCA. IRS2 has been shown to regulate cell size and
apoptosis in pancreatic beta cells through the homeobox transcription
factor Pdx1 (Withers et al. 1998, Kushner et al. 2002, Linghor et al.
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2003). Interestingly Pdx1 was shown to bind to the promoter region of
FAM3B regulating glucose stimulated expression of FAM3B (Burkhardt
et al. 2008).
As stated previously, PDCD4 interacts with EIF4A and EIF4G.
Insulin has been shown to up-regulate the interaction of EIF4G with
EIF3 through the AKT/PI3K/mTOR pathway (Harris et al., 2006). Upregulation of phosphorylated AKT also down-regulates PDCD4 in
cancer cells (Fasan et, al. 2011). Overexpression of HSC70 was also
shown to increase the solubility of EIF4G (Cuesta, et al., 2000). This
relationship may play a role in MSA as EIF4G1 has been implicated in
familial PD (Chartier-Harlin, et al., 2011).
Inhibition of PKC-delta increased expression of PDCD4 in Huh7
hepatoma cells (Nakashima et, al. 2010). It is possible SNCA is directly
responsible for changes in PDCD4 expression. PKC-delta binds to and
is down-regulated by SNCA (Jin et, al. 2011). This down-regulation of
PKC-delta could result in the increase in PDCD4 expression observed in
C6 cells treated with SNCA.
Conclusion
PDCD4 and FAM3B change in expression due to the treatment
with SNCA in C6 Oligodendrocyte-like cells. This change appeared to
be dose and time dependent. Protein expression also appeared to
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correspond to the CASP3 protein expression in C6 oligodendrocyte-like
cells described previously in chapter 3 and HSC70 described in chapter
2. In MSA patients, CASP3, PDCD4 and FAM3B were expressed in
fibers containing MBP, suggesting a relationship between these
proteins and demyelination due to oligodendrocyte apoptosis.
To date, little is known about PDCD4 and FAM3B and their roles
in apoptosis. Although the studies discussed have shown that these
two genes are involved in apoptosis, specific mechanisms have yet to
be resolved. The data presented here represent the first time FAM3B
has been stained for in a patient with a synucleinopathy.
Understanding how PDCD4 and FAM3B are regulated and involved in
apoptosis and regulated by the mTOR/AKT/PI3K pathway in MSA could
generate new targets of treatment for the disease.
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CHAPTER VI
PROTEIN HOOK HOMOLOG 3 LEVELS DECREASE IN THE GRANULAR
CELL LAYER OF THE MULTIPLE SYSTEMS ATROPHY CEREBELLUM
Introduction
As discussed above, HOOK3 is a member of the Hook family of
proteins. HOOK family proteins bind to microtubules and are
responsible for endocytic trafficking (Kramer et, al. 1999). HOOK3 has
been shown to be involved in defining the conformation of the Golgi
complex (Walenta et al. 2001).
HOOK3 also has been shown to be involved with the innate
immune system. HOOK3 regulates the expression of scavenger
receptor A (SR-A, MSR1). Blockage of HOOK3 by the Samonella SpiC
protein results in the disruption of the Golgi complex (Shortland et al.
2003). Additionally this disruption interferes with the phagosomelysosome network.
Based on the DNA microarray and western blot data discussed in
chapter 4, there appears to be a relationship between SNCA and
HOOK3. As stated previously, SNCA has been shown to occur in glial
cytoplasmic inclusions (GCI) of the white matter tracts in MSA.
However oligodendrocytes do not produce SNCA. As such there must
be a source in proximity to the white matter tracts of SNCA.
To look for the influence of HOOK3 in MSA, I examined the
cerebellum for changes in protein expression. The cerebellar folia
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consist of 4 layers: molecular layer, Purkinje cell layer, granular cell
layer and white matter tracts. The granule cells account for about half
of the neurons in the central nervous system. Excitatory output from
the pontine nuclei travel through myelinated axons called mossy fibers
in the white matter tracts to the cerebellar granule cells. Excitatory
granule cell output travels along parallel fibers through the Purkinje
layer into the molecular layer where they synapse on the dendrites of
the Purkinje cells. In MSA, patients appear to lose a percentage of
several cerebellar cell types as the disease progresses. Myelinated
fibers in the white matter tracts and, Purkinje cell numbers are
reduced and the granule cell layer also loses a significant number of
cells.
This experiment had three objectives. First, I sought to confirm
SNCA is normally expressed in the cerebellum. Second, SNCA was
shown to decrease expression of HOOK3 in C6 oligodendrocyte-like
cells. If SNCA is involved in regulation of HOOK3 then SNCA and
HOOK3 should be co-localized in the cerebellum. Lastly, if HOOK3
protein is expressed by oligodendrocytes, then expression of HOOK3
should be co-localized with Mylein Basic Protein (MBP), a marker for
oligodendrocytes. Using Immunocytochemistry (ICC) methods
cerebellar tissue from control and MSA patients was evaluated to
determine the expression of these proteins.
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Methods
Immunocytochemistry
Human cerebellum slides were obtained from the New York Brain
Bank at Columbia University. Slides were de-paraffinized and
rehydrated using a series of xylene and alcohol washes followed by
TBS. Next heat antigen retrieval was used to unmask proteins. Slides
were placed in 10mM Sodium Citrate buffer (pH 6.0) for 40 min at 80
ºC. After antigen retrieval slides were washed in 3% H2O2 for 5 min
followed by two washes in TBS. Slides were next blocked for 1 hour in
3% normal donkey serum. After blocking, slides were incubated at 4
o

C overnight in goat anti-HOOK3 (Santa Cruz ©) at 1:100. Slides were

then washed in TBS and incubated in biotinylated donkey anti-goat
secondary antibody (Santa Cruz©) at 1:100 for 30 min. Slides were
then washed three times in TBS. To detect biotin labeled secondary, a
Vector ABC-DAB kit was used following the manufacturer’s protocol
(Vector© Labs). Slides were washed three times in TBS. DAB
substrate was added to Tris-HCl buffer (pH 7.5) and placed on slides
for 10 min. Next to double label HOOK3 with either SNCA or MBP,
slides were rinsed in dH20 and washed three times in TBS. Slides were
next blocked for 1 hour in 3% normal goat serum. After blocking slides
were incubated at 4 oC overnight in either rabbit anti-SNCA (Sigma ©)
at 1:200 or anti-MBP at 1:50 (Santa Cruz©). Slides were then washed
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in TBS and incubated in biotinylated goat anti-rabbit secondary
antibody (Santa Cruz©) at 1:100 for 30 min. Slides were then washed
three times in TBS. To detect biotin-labeled secondary, a Vector ABCAP kit in combination with Vector© AP substrate kit was used following
the manufacturers protocol (Vector© Labs). Levamasole (Vector) was
added to quench endogenous AP per the manufacturer’s
recommendations. Slides were washed three times in TBS then rinsed
in H20 and dehydrated through a series of xylene-alcohol washes and
cover slipped using Permimount (ThermoFisher).
Photographs were taken using the Spot Cooled Color Digital
Camera system as described in chapter 2. Image analysis for DAB
(brown) and AP (red) were completed using the ImageJ (nih.gov) color
deconvolution tool. As described in the previous chapter, this tool
allows the user to select red and brown tones in an image. After
selection, red and brown colors were separated by the program and
measured for the amount of area stained using the measure function
of ImageJ. Area of stain measured was converted to percent area
stained. A t-test was then completed using Statview 5.0 as described
above.
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Results
HOOK3 Staining in Control Patients Co-localizes with SNCA in the
Granule Cell Layer and White Matter Tracts of the Cerebellum
To determine if HOOK3 expression was altered in MSA brain,
cerebellar tissue from patients and controls were double labeled for
HOOK3 and SNCA. Using a lower power magnification, it appeared
that SNCA and HOOK3 stained in the granule cell layer of control
patients but was reduced in patients with MSA (Figure 13). Additionally
it appeared that HOOK3 stains in the white matter tracts of control
patients, but may double label with SNCA in MSA patients.
Using higher power magnification, staining of HOOK3 was found
heaviest in the granule cell layer in the cytoplasmic spaces of control
patients (Figure 14). Imagej (nih.gov) was used to measure the area
of HOOK3 staining. Using a t-test, HOOK3 was found to decrease by
approximately 24% in MSA patients compared to controls (P=0.012).
SNCA also appears to decrease with HOOK3 in granule cells. Control
patients had approximately 54% more area stained for SNCA than
MSA patients.
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Figure 13. Two examples of ICC-stained paraffin-embedded tissue from a control and
MSA cerebellum. HOOK3 was resolved using DAB (brown) and SNCA was resolved
using AP (red); PC = Purkinjie Cell, ML = Molecular Layer, GCL = Granule Cell Layer,
WM = White Matter Tract. A. Control patients show SNCA and HOOK3 protein in the
granule cell layer. B. Texas red image of SNCA in the Granule cell layer of control
patients. C. MSA patients show loss of HOOK3 and SNCA in the granular cell layer.
D. Texas red image of MSA patients show a loss of SNCA in the granule cell layer and
the presence of SNCA in the white matter tracts.
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Figure 14. ICC analysis of HOOK and SNCA the Granule Cell Layer (GCL) in MSA
cerebellum. HOOK3 was resolved using DAB (brown) and SNCA was resolved using
AP (red); PC = Purkinjie Cell, ML = Molecular Layer, GCL = Granule Cell Layer, WM =
White Matter Tract. A. Control patient shows SNCA and HOOK3 protein in the granule
cell layer. B. MSA patient shows loss of HOOK3 and SNCA in the granular cell layer.
Staining was measured using Imagej and analyzed using a t-test. MSA patients
showed a 54% reduction in SNCA staining (p<0.001). MSA patients also showed
24% reduction in HOOK3 staining (p= 0.012), N=5, Error bars = 1 S.E.

White matter tracts were also evaluated for changes in
expression of HOOK3 and SNCA. In control patients, only HOOK3
appeared in the white matter tracts (Figure 15a). In MSA patients
SNCA and HOOK3 appear to co-localize in the white matter tracts
(Figure 15b). ImageJ was used to separate the red and brown colors
using the color deconvolution tool. In control patients, HOOK3 was

71

single labeled in 2.5% of the white matter tract. In MSA patients, the
majority of HOOK3 double labeled with SNCA covering 2.6% of the
white matter tract.

Figure 15. High magnification of two examples of ICC-stained paraffin-embedded
tissue from a control and MSA cerebellum. HOOK3 was resolved using DAB (brown)
and SNCA was resolved using AP (red); A. Control patients show HOOK3 protein in
the white matter tracts B. MSA patients double labeling of HOOK3 and SNCA in the
white matter tracts. Image analysis of singly labeled SNCA shows an increase in cells
labeled with SNCA in patients (p=0.03). Cells singly labeled with HOOK3 had
significantly higher expression in control patients (p<0.001). MSA patients show a
majority of cells stained for HOOK3 and SNCA (p<0.001), N=3.

HOOK3 Co-localizes with MBP in the White Matter Tracts and the
Granule Cell Layer of the Cerebellum
Using ICC methods, HOOK3 and MBP staining were evaluated in
control and MSA patients. It appeared that HOOK3 stained in-between
the granule cells and around Purkinje cells of control patients (Figure
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16 A & D). Using texas red fluorescence to better resolve MBP, it
shows co-localization of MBP and HOOK3 in-between cells (Figure 16 C
& F). Staining in MSA patients showed fragmentation of MBP and a loss
of HOOK3 in-between granule cells. Using an overlay of HOOK3 in
brightfield and MBP in texas red, it appeared the remaining tissue was
double labeled. MBP staining decreased from 21.3% in controls to
9.4% of the granule cell layer in MSA patients. HOOK3 staining
decreased from 45.8% in controls to 32.9% of the granule cell layer in
MSA patients. Cells double labeled with HOOK3 and MBP decreased
from 3.8% in controls to 0.49% of the granule cell layer in MSA
patients.
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Figure 16. High power images of two examples of control and MSA granule cell layer.
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Figure 16 – Continued
HOOK3 was resolved using DAB (brown) and MBP was resolved using AP (Texas red)
PC = Purkinjie Cell, GCL = Granule Cell Layer. Control patients show diffuse labeling of
MBP and HOOK3 protein in the granule cell layer (A,B & C). A. Brightfield highlights
HOOK3 in-between the Granule cells and Purkinjie cells. B. Texas red identifies MBP in
locations approximate to HOOK3 staining. C. Overlay of the brightfield and texas red
images shows co-localization of MBP and HOOK3. MSA patients appear to lose both
HOOK3 and MBP in the granular cell layer (D,E &F). D. Brightfield light shows a limited
amount of HOOK3 in the granule cell layer. E. Texas red identifies MBP in locations
approximate to HOOK3 staining. F. Overlay of the brightfield and texas red images
shows co-localization of MBP and HOOK3 in the remaining tissue of patients. MBP
staining decreased from 21.3% in controls to 9.4% of the granule cell layer in MSA
patients. HOOK3 staining decreased from 45.8% in controls to 32.9% of the granule cell
layer in MSA patients. Cells double labeled with HOOK3 and MBP decreased from 3.8%
in controls to 0.49% of the granule cell layer in MSA patients.

Analysis of the white matter tracts showed a decrease in MBP

and HOOK3 (Figure 17). In control patients, HOOK3 appeared best in
rounded cell bodies. MBP stained the entire field including the areas of
HOOK3. In MSA patients, the area of MBP staining decreased from a
mean of 53% to 24% of the white matter tract (p=0.0002). HOOK3
staining also decreased from a mean area in control patients of 6.1%
to 3.9% in MSA patients (p=0.043). Despite the decrease in staining,
identification of HOOK3 and MBP was still possible.
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Figure 17. High power images of two examples of control and MSA white matter tracts.
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Figure 17 – Continued
HOOK3 was resolved using DAB (brown) and MBP was resolved using AP (Texas red).
Control patients show cell bodies labeled with MBP and HOOK3 protein (A,B & C). A.
Brightfield shows HOOK3 staining in cell bodies located in the white matter tracts. B.
Texas red image shows diffuse staining for MBP in the white matter tracts. C. Overlay of
brightfield and texas red images shows double labeling of HOOK3 and MBP in cell
bodies located in the white matter tracts. MSA patients appeared to lose cell bodies
containing HOOK3 and MBP (D,E & F). D. Brightfield showed HOOK3 located in the
white matter tracts. E. Texas red shows fragmented expression of MBP. F. Overlay of
brightfield and texas red images showed HOOK3 and MBP co-localize in the white
matter tracts. Analysis of staining showed a significant decrease in MBP and HOOK3
(p=0.0002 & 0.043) N=4.

Discussion
HOOK3 appeared to double label with MBP confirming HOOK3 in
Oligodendrocytes. Staining occurred in both myelinated fibers passing
through the granule cell layer and in the white matter tracts. HOOK3
and SNCA staining in the granule cell layer of cerebellum in MSA
patients decreased by 24% and 54% respectively. In control patients
HOOK3 appeared to travel in long strands through the granule cell
layer. SNCA appeared to be co-localized with HOOK3 along these
strands in round formations. HOOK3 and SNCA staining in the white
matter tracts of MSA patients appeared to be solely in cell bodies.
Control patients only stained for HOOK3 in the white matter tracts.
HOOK3 is dependent on microtubules. As stated previously,
HOOK3 uses microtubules to traffic endocytotic bodies in the cell, and
to stabilize the Golgi complex. HOOK3 also uses microtubules for
regulating neurogenesis and binding the centromere (Xuecai et al.,
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2010). Given the ability of SNCA aggregation to hydrolyze
microtubules, it is likely that HOOK3 normal functions are being
disrupted. This could result in fragmentation of the Golgi, or problems
with the proteasome-lysosome complex as seen in other diseases.
The reduction of HOOK3 in the granule cell layer and the
decrease of HOOK3 protein with SNCA treatment in C6 cells suggest
that the regulation of HOOK3 may be tied to the expression of SNCA.
SNCA is already known to cause blockage of the lysosome when it is
misfolded (Cuervo et al., 2004). Batten’s disease (juvenile neuronal
ceroid lipofuscinosis) is a lysosomal storage disease causing the
accumulation of lipofuscins in body tissues. Defects in this disease
result in problems with the intercellular trafficking functions of HOOK1
(Luiro et al., 2004, Kama 2007). These observations suggest a
common relationship with the lysosome, SNCA and HOOK3. Further
research is necessary to determine if SNCA is interfering with normal
HOOK3 function.
Conclusion
HOOK3 co-localizes with SNCA in the granule cell layer of control
patients. Staining for HOOK3 appeared to occur in spaces between
granule cells. HOOK3 and SNCA decrease in protein expression in the
granule cell layer of MSA patients. Interestingly, as HOOK3 and SNCA
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decrease in the granule cell layer, HOOK3 co-localizes with SNCA in
the white matter tracts of MSA patients.
To determine what cell type HOOK3 occurs in, tissue was double
labeled with HOOK3 and MBP. HOOK3 co-localizes with MBP in the
granule cell layer of control and MSA patients. HOOK3 also co-localized
with MBP in cell bodies located in the white matter tracts. Both HOOK3
and MBP decreased in expression in the white matter tracts of MSA
patients.
Collectively this suggests that HOOK3 protein has a relationship
with MSA. HOOK3 expression appears to change due do the presence
of SNCA and the loss of oligodendrocytes. Further research is
necessary to understand how HOOK3 interacts with SNCA.
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CHAPTER VII
CONCLUSION
C6 cells treated with Retinoic Acid to induce an oligodendrocytelike phenotype are useful in modeling synucleopathies. C6 cells were
able to take up wild-type SNCA and a mutant SNCA known to PD,
A53T. Uptake did not appear to change due to the amount of time cells
were in culture. Cells also demonstrated changes in expression of
HSC70, a protein known to accumulate in GCIs, in a dose and time
dependent manner.
In addition to uptake of SNCA, cells appeared to truncate the
SNCA protein. In a study using SNCA with a C-terminus truncation,
apoptosis was shown to occur in glial cells (Stefanova et al., 2001). In
the present study, treatment with SNCA showed an increase in trypan
blue cell death. Changes in the protein expression of CASP3 and other
apoptosis-related proteins, PDCD4 and FAM3B were also found to
change in a dose and time dependent manner. These changes in
apoptotic proteins appeared to have occurred faster at higher
concentrations of SNCA treatment, followed by a decrease in
expression. This change in apoptosis-related protein expression was
similar to the change in expression of HSC70.
DNA Microarrays are useful in identifying expression changes
related to SNCA treatment. Using our C6 cell model several genes not
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previously described in MSA were identified. To follow up, one gene of
interest, HOOK3 was examined for changes in protein expression.
HOOK3 was found to decrease in a dose and time dependent manner
when cells were treated with SNCA.
To determine if HOOK3 plays a role in MSA, cerebellar tissue was
examined for SNCA and HOOK3 expression. HOOK3 and SNCA
appeared to co-localize in the granule cell layer of control patients, and
in the white matter tracts of MSA patients. The expression of HOOK3
and SNCA in the granule cell layer appeared to decrease in MSA
patients when compared to control patients. When taken together with
SNCA induced changes in C6 cell HOOK3 expression, it appears that
HOOK3 may play a role in MSA.
STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) is a database of direct and indirect protein
interactions (STRING-db.org, Jensen et al. 2009). The data are
compiled and scored for confidence in the interactions using
textmining, curated databases, direct experiments, co-expression and
gene fusions. Using this database to analyze the genes described in
this paper, it appears that many are involved with the AKT pathway,
PKC-delta and apoptosis (Figure 18).
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Figure 18. Simplified interaction map of genes influenced by SNCA in C6 cells.
STRING, a database for known and predicted protein-protein interactions, identifies
potential interactions based on evidence collected from several databases. Genes
identified in this dissertation are colored, linking genes are grey. Intensity of lines
linking proteins represents the confidence associated with an interaction based on
the curated databases. It appears that the genes of interest are clustered around
the AKT pathway.

PI3K, Phosphatidylinositol 3-kinase, is known to accumulate in
MSA (Wenning et al. 2008). It also has been shown to regulate
expression of HSC70 (Bański et al. 2010). IRS2 identified in the DNA
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microarray has been shown to regulate the expression of PI3K (Shaw,
2001). Upregulation of IRS2 could be one mechanism regulating
HSC70.
IRS2 through PI3K could also regulate FAM3B. Beta cells treated
with glucose showed an increase in FAM3B expression. Treatment with
glucose and inhibitors of PI3K, CREB and PKC-alpha, also inhibit
expression of FAM3B (Wang et al., 2008).
Control of PDCD4 can be accomplished through several
mechanisms. The up-regulation of phosphorylated Akt appears to
down-regulate PDCD4 in cancer cells (Fasan et al. 2011). PDCD4
expression appears to be up-regulated by PKC-delta (Nakashima et, al.
2010). It has been shown that PKC-delta is down-regulated in turn by
SNCA (Jin et al. 2011).
Interestingly down-regulation of PDCD4 seen at the higher
dosage and duration of treatment could explain the increase in
expression of ERBB3. As shown in chapter 3, ERBB3 had increased
expression at the higher concentration of SNCA treatment. ERBB3 has
been shown to function as a regulator of the Smad pathway via SOS
and GRB2 (Goodearl et al. 2001). PDCD4 has been shown to be
involved with TGF-beta induced apoptosis via the Smad pathway
(Davis et al., 2008). This suggests a potential relationship between
these two proteins.
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Intercellular trafficking by HOOK3 may also play a role in the
AKT-mediated apoptosis. The HOOK family of proteins are known to
function in the endocytic trafficking mechanism FTS/Hook/p107(FHIP)
along with SNARE complexes (Xu et al. 2008). SNARE complexes with
HSC70 and LAMP-2a for importation of SNCA into the lysosome
(Cuervo et al. 2004). FTS (AKTIP) was shown to control
phosphorylation of AKT and regulate apoptosis (Remy and Michnick
2004). However, expression of HOOK3 does not resemble the
expression of CASP3, HSC70, PDCD4 or FAM3B. HOOK3 expression
appeared to decrease in a dose and time dependent manner. The
decrease in HOOK3 expression could be an attempt for the cell to shift
traffic from the golgi to the lysosome complex increasing clearance of
SNCA, rather than an activation of apoptosis.
However after 2 days of treatment the highest dosage of SNCA
was the only group with a significant decrease in HOOK3, which is
similar to the apoptosis-related proteins discussed above. Secondly a
shift in the peak of CASP3 and related protein expression to the lower
concentrations of SNCA may be related to the decrease of HOOK3 in
the lower treatment groups of SNCA. This suggests that regulation of
the AKT pathway may be dependent on not only the conditions of
endocytic traffic but also expression of apoptotic proteins.
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Overall this study establishes a new cell model for MSA. This
model can be used to identify new target proteins of interest using
various techniques. It also proposes how SNCA may influence cell
death and intercellular trafficking. Further research on how SNCA is
involved and disrupts intercellular trafficking is necessary to
understand how apoptosis is chronically induced in MSA patients.
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